Treating depression in children and adolescents: what options now?

Abstract:

:There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children and adolescents, and there is evidence from randomised, double-blind, placebo-controlled trials of benefit for both approaches. However, not all medication trials have been positive. In addition, there have been increasing concerns about specific safety issues related to the use of medications to treat depression, with an overall finding of mood-related adverse effects, including suicide attempts, in 4% of active drug versus 2% of placebo recipients in controlled trials involving children and adolescents. This has resulted in regulatory actions in a number of countries that have ranged from the declaration of contraindication for most antidepressants (in Great Britain), to relegation of antidepressants to a second-line intervention (in New Zealand) to a Black Box warning (in the US). It can be concluded that best practice combines treatment with both medication and psychotherapy, and that important safety issues must be monitored carefully when children and adolescents are treated for depression. On balance, there appears to be evidence of the benefit for antidepressant medications in children and adolescents, which outweigh safety concerns.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Varley CK

doi

10.2165/00023210-200620010-00001

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

1-13

issue

1

eissn

1172-7047

issn

1179-1934

pii

2011

journal_volume

20

pub_type

杂志文章,评审
  • CNS manifestations of cytomegalovirus infections: diagnosis and treatment.

    abstract::Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216050-00003

    authors: Maschke M,Kastrup O,Diener HC

    更新日期:2002-01-01 00:00:00

  • HIV-related movement disorders: epidemiology, pathogenesis and management.

    abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216100-00002

    authors: Cardoso F

    更新日期:2002-01-01 00:00:00

  • Blonanserin: a review of its use in the management of schizophrenia.

    abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202620-000000000-00000

    authors: Deeks ED,Keating GM

    更新日期:2010-01-01 00:00:00

  • Remifentanil update: clinical science and utility.

    abstract::The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418150-00004

    authors: Beers R,Camporesi E

    更新日期:2004-01-01 00:00:00

  • Neuroprotection in multiple sclerosis: a therapeutic approach.

    abstract::Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0093-7

    authors: Maghzi AH,Minagar A,Waubant E

    更新日期:2013-10-01 00:00:00

  • Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

    abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317070-00004

    authors: Hesse LM,von Moltke LL,Greenblatt DJ

    更新日期:2003-01-01 00:00:00

  • Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.

    abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200317120-00005

    authors: Fogelman Y,Vinker S,Guy N,Kahan E

    更新日期:2003-01-01 00:00:00

  • Role of the melatonin system in the control of sleep: therapeutic implications.

    abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721120-00004

    authors: Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

    更新日期:2007-01-01 00:00:00

  • VMAT2 Inhibitors in Neuropsychiatric Disorders.

    abstract::The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0580-y

    authors: Tarakad A,Jimenez-Shahed J

    更新日期:2018-12-01 00:00:00

  • Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

    abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0307-2

    authors: Logallo N,Kvistad CE,Nacu A,Thomassen L

    更新日期:2016-02-01 00:00:00

  • Pharmacotherapy for Friedreich ataxia.

    abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923030-00003

    authors: Tsou AY,Friedman LS,Wilson RB,Lynch DR

    更新日期:2009-01-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

    abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00756-y

    authors: Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

    更新日期:2020-09-01 00:00:00

  • Biological markers of age-related memory deficits: treatment of senescent physiology.

    abstract::In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620020-00006

    authors: Foster TC

    更新日期:2006-01-01 00:00:00

  • Overview of the therapeutic management of insomnia with zolpidem.

    abstract::Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418001-00005

    authors: Lee YJ

    更新日期:2004-01-01 00:00:00

  • Pharmacotherapy for parents with attention-deficit hyperactivity disorder (ADHD): impact on maternal ADHD and parenting.

    abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11633910-000000000-00000

    authors: Chronis-Tuscano A,Stein MA

    更新日期:2012-09-01 00:00:00

  • Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

    abstract::Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115020-00004

    authors: Brambilla F

    更新日期:2001-01-01 00:00:00

  • Spotlight on oxcarbazepine in epilepsy.

    abstract::Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418010-00006

    authors: Bang LM,Goa KL

    更新日期:2004-01-01 00:00:00

  • Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

    abstract:BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...

    journal_title:CNS drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11634500-000000000-00000

    authors: De Hert M,Yu W,Detraux J,Sweers K,van Winkel R,Correll CU

    更新日期:2012-09-01 00:00:00

  • Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

    abstract:BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620050-00005

    authors: Bordier P,Garrigue S,Lanusse S,Margaine J,Robert F,Gencel L,Lafitte A

    更新日期:2006-01-01 00:00:00

  • Mixed Anxiety and Depression : Diagnosis and Treatment Options.

    abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199809040-00003

    authors: Bakish D,Habib R,Hooper CL

    更新日期:1998-04-01 00:00:00

  • Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

    abstract::All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0177-z

    authors: Bonoldi I,Howes OD

    更新日期:2014-07-01 00:00:00

  • The Therapeutic Role of Gangliosides in Neurological Disorders.

    abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199401030-00006

    authors: Schneider JS

    更新日期:1994-03-01 00:00:00

  • Nusinersen: A Review in 5q Spinal Muscular Atrophy.

    abstract::Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0545-1

    authors: Hoy SM

    更新日期:2018-07-01 00:00:00

  • Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

    abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-014-0191-1

    authors: Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

    更新日期:2014-11-01 00:00:00

  • Drug Repurposing in Parkinson's Disease.

    abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0548-y

    authors: Athauda D,Foltynie T

    更新日期:2018-08-01 00:00:00

  • Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.

    abstract:BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...

    journal_title:CNS drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40263-016-0351-6

    authors: Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore K

    更新日期:2016-09-01 00:00:00

  • Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

    abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0301-8

    authors: Calsolaro V,Edison P

    更新日期:2015-12-01 00:00:00

  • Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.

    abstract::Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0250-2

    authors: Mackie S,Winkelman JW

    更新日期:2015-05-01 00:00:00

  • Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

    abstract::Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418130-00003

    authors: Desai AK,Grossberg GT,Sheth DN

    更新日期:2004-01-01 00:00:00